Latest Breaking News On - Advanced solid - Page 12 : comparemela.com

Message : Required fields NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors Partial Response Observed in a Patient with Refractory Gastroesophageal Junction Cancer REHOVOT, Israel, June 4, 2021 - Purple Biotech Ltd. ( Purple Biotech , or the Company ) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, announced today the presentation of new data from the first dose level cohort of its ongoing Phase 1/2 clinical trial of NT219, at the 2021 ASCO Annual Meeting, being held virtually June 4-8, 2021. The Phase 1/2 study is evaluating NT219 as monotherapy for the treatment of solid tumors, in addition to a subsequent dose escalation of NT219 in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the treatment of recu

United statesSouth koreaGil efronBertrandc liangMegan humphreysAlberto bessudoChuck padalaExchange commissionCompany contactPurple biotech ltdCalifornia cancer associates for research excellenceDrug administrationBristol myers squibbCoeptis pharmaceuticalsMinimal adverse eventsInitial clinical data